RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors. 

Taofeek K. Owonikoko, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.82 MB
Released: January 21, 2021


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Related Content

Podcast episode with expert insights on new data from WCLC 2020 helping to improve outcomes for patients with early-stage lung cancer, from Clinical Care Options (CCO)

Jamie E. Chaft, MD Released: February 24, 2021

Get expert insights from Clinical Care Options (CCO) on how to talk to your patients with lung or thyroid cancer about precision medicine

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: February 23, 2021

In this slideset from Clinical Care Options (CCO), Joel W. Neal, MD, PhD discusses antibody-drug conjugates within the clinical trial setting in NSCLC

Joel W. Neal, MD, PhD Released: February 16, 2021

Downloadable slideset with key highlight data from the 2020 WCLC Virtual Symposium from Clinical Care Options (CCO)

Shirish M. Gadgeel, MD person default Nicolas Girard, MD, PhD Released: February 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.